Rakovina Therapeutics Inc. (TSXV:RKV)
Canada
· Delayed Price · Currency is CAD 0.135
-0.005 (-3.57%)
At close: Mar 9, 2026
Rakovina Therapeutics Balance Sheet
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Cash & Equivalents | 0.82 | 1.31 | 0.44 | 0.9 | 2.81 | 0 | Upgrade
|
| Cash & Short-Term Investments | 0.82 | 1.31 | 0.44 | 0.9 | 2.81 | 0 | Upgrade
|
| Cash Growth | 222.41% | 200.87% | -51.35% | -68.10% | 40164771.43% | - | Upgrade
|
| Other Receivables | 0.15 | 0.08 | 0.02 | 0.01 | 0.07 | 0 | Upgrade
|
| Receivables | 0.15 | 0.08 | 0.02 | 0.01 | 0.07 | 0 | Upgrade
|
| Prepaid Expenses | 0.39 | 0.4 | 0.18 | 0.16 | 0.19 | - | Upgrade
|
| Other Current Assets | 0.32 | 0.47 | - | - | - | - | Upgrade
|
| Total Current Assets | 1.69 | 2.26 | 0.63 | 1.07 | 3.07 | 0 | Upgrade
|
| Other Intangible Assets | 3.58 | 3.98 | 4.52 | 5.05 | 5.59 | - | Upgrade
|
| Total Assets | 5.27 | 6.24 | 5.15 | 6.12 | 8.66 | 0 | Upgrade
|
| Accounts Payable | 0.68 | 0.33 | 0.01 | 0.03 | 0.04 | - | Upgrade
|
| Accrued Expenses | 0.06 | 0.2 | 0.15 | 0.08 | 0.07 | 0 | Upgrade
|
| Current Portion of Long-Term Debt | 1.44 | 1.42 | - | - | - | - | Upgrade
|
| Total Current Liabilities | 2.18 | 1.94 | 0.15 | 0.11 | 0.11 | 0 | Upgrade
|
| Long-Term Debt | 1.16 | - | 1.33 | - | - | - | Upgrade
|
| Other Long-Term Liabilities | 0.04 | - | - | - | - | - | Upgrade
|
| Total Liabilities | 3.38 | 1.94 | 1.49 | 0.11 | 0.11 | 0 | Upgrade
|
| Common Stock | 18.45 | 16.45 | 13.6 | 13.58 | 13.57 | 0 | Upgrade
|
| Additional Paid-In Capital | 5.22 | 2.85 | 0.91 | 0.75 | 0.49 | - | Upgrade
|
| Retained Earnings | -21.79 | -15 | -10.93 | -8.31 | -5.52 | -0 | Upgrade
|
| Comprehensive Income & Other | 0 | 0 | 0.08 | - | - | - | Upgrade
|
| Shareholders' Equity | 1.89 | 4.3 | 3.66 | 6.01 | 8.54 | -0 | Upgrade
|
| Total Liabilities & Equity | 5.27 | 6.24 | 5.15 | 6.12 | 8.66 | 0 | Upgrade
|
| Total Debt | 2.6 | 1.42 | 1.33 | - | - | - | Upgrade
|
| Net Cash (Debt) | -1.77 | -0.11 | -0.9 | 0.9 | 2.81 | 0 | Upgrade
|
| Net Cash Growth | - | - | - | -68.10% | 40164771.43% | - | Upgrade
|
| Net Cash Per Share | -0.12 | -0.01 | -0.13 | 0.13 | 0.52 | - | Upgrade
|
| Filing Date Shares Outstanding | 21.15 | 14 | 7.01 | 6.98 | 6.98 | - | Upgrade
|
| Total Common Shares Outstanding | 21.15 | 14.05 | 7.01 | 6.98 | 6.98 | - | Upgrade
|
| Working Capital | -0.49 | 0.32 | 0.48 | 0.96 | 2.96 | -0 | Upgrade
|
| Book Value Per Share | 0.09 | 0.31 | 0.52 | 0.86 | 1.22 | - | Upgrade
|
| Tangible Book Value | -1.69 | 0.32 | -0.86 | 0.96 | 2.96 | -0 | Upgrade
|
| Tangible Book Value Per Share | -0.08 | 0.02 | -0.12 | 0.14 | 0.42 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.